To determine the relative effectiveness of moderate versus more aggressive lipid lowering,
and of low dose anticoagulation versus placebo, in delaying saphenous vein coronary bypass
graft atherosclerosis and preventing occlusion of saphenous grafts of patients with saphenous
vein coronary bypass grafts placed 1 to 11 years previously.
Platelet Drug Trial in Coronary Disease Progression
Completed
National Heart, Lung, and Blood Institute (NHLBI)
Phase 3
1979-12-01
To determine the effectiveness of the platelet inhibitor drugs dipyridamole and aspirin in
reducing the angiographic progression of coronary artery disease over a five-year period and
to test the predictive value of the platelet survival half-life in identifying patients with
more rapid progression of coronary disease and development of its complications.
Platelet-Inhibitor Drug Trial in Coronary Angioplasty
Completed
National Heart, Lung, and Blood Institute (NHLBI)
Phase 3
1983-09-01
To determine the effectiveness of dipyridamole and aspirin in prevention of restenosis of the
dilated lesion in patients who had undergone percutaneous transluminal coronary angioplasty
(PTCA). Secondary aims were to determine the effectiveness of platelet inhibitor therapy in
reducing the incidence of coronary events and the severity and incidence of angina.
To determine whether recurrent stenosis following carotid endarterectomy could be reduced by
pre- and post-operative oral administration of platelet-inhibiting drugs.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
